ABSTRACT
Peptide-based immunotherapy does not usually elicit strong immunological and clinical responses in patients with end-stage cancer, including sarcoma. Here we report a myxofibrosarcoma patient who showed a strong clinical response to peptide vaccinations and whose immune responses were reboosted by anti-PD1 therapy combined with peptide vaccinations. The 46-year-old man showed a strong response to the peptide vaccinations (papillomavirus binding factor peptide, survivin-2B peptide, incomplete Freund's adjuvant, and polyethylene glycol-conjugated interferon-alpha 2a) and subsequent wide necrosis and massive infiltration of CD8+ T cells in a recurrent tumor. The patient's immune responses weakened after surgical resection; however, they were reboosted following the administration of nivolumab combined with peptide vaccinations. Thus, anti-PD1 therapy combined with peptide vaccinations might be beneficial, as suggested by the observations in this sarcoma patient.
Subject(s)
Cancer Vaccines/immunology , Fibroma/immunology , Fibroma/therapy , Fibrosarcoma/immunology , Fibrosarcoma/therapy , Immunization, Secondary , Peptides/immunology , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Biomarkers, Tumor , Cancer Vaccines/administration & dosage , Combined Modality Therapy , Fibroma/diagnosis , Fibrosarcoma/diagnosis , Humans , Immunohistochemistry , Immunophenotyping , Male , Middle Aged , Positron Emission Tomography Computed Tomography , Tomography, X-Ray ComputedABSTRACT
A 63-year-old man with multiple HCC in his left liver lobe was enrolled as the first patient in a pilot study of boron neutron capture therapy (BNCT) involving the selective intra-arterial infusion of a (10)BSH-containing water-in-oil-in-water emulsion ((10)BSH-WOW). The size of the tumorous region remained stable during the 3 months after the BNCT. No adverse effects of the BNCT were observed. The present results show that (10)BSH-WOW can be used as novel intra-arterial boron carriers during BNCT for HCC.